Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevaciz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Eye (London) 2009-11, Vol.23 (11), p.2042-2045
Hauptverfasser: Wu, P-C, Chen, Y-J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2045
container_issue 11
container_start_page 2042
container_title Eye (London)
container_volume 23
creator Wu, P-C
Chen, Y-J
description Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 ( P =0.017). The final mean central retinal thickness was 214.1±36.3  μ m, with a mean decrease of 59.8  μ m from the pre-treatment value ( P =0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.
doi_str_mv 10.1038/eye.2008.404
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_734134044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>734134044</sourcerecordid><originalsourceid>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</originalsourceid><addsrcrecordid>eNp90c1rFDEUAPAgFru23jzLIKiXzjbJ5GPGWymtLRS8WOgtvMkkmmVmsiYzK9u_vm_ZxYJIySGH_PI-CXnP6JLRqj53W7fklNZLQcUrsmBCq1IKKV6TBW0kLTnnD8fkbc4rSvFR0zfkmDVMMiX5gpjbcUqwCVNy0BdhXDk7hTgW0Ret24ANj_MAbeFjKoZtXAdb2F8xxdChHl3cQLZzDyk8wu7b14KVWwcJfd_HP-W8PiVHHvrs3h3uE3J_ffXj8qa8-_7t9vLirrSS06nkulHWa6-s7joJlINlTmrHatUJ5kTjW-ikoK2gVnsulO5aPMCqSlGtfHVCvuzjrlP8Pbs8mSFk6_oesMo5G10JVuGEBMrPL0rOeC0rxRF-_Aeu4pxG7AJNXTVCS4bobI9sijkn5806hQHS1jBqdvsxuB-z24_B7Mg_HGLO7eC6Z3xYCIJPB4CThd4nGG3Ifx3nTGLLCl25dxmfxp8uPRf338RPfjuoAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>218394751</pqid></control><display><type>article</type><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Wu, P-C ; Chen, Y-J</creator><creatorcontrib>Wu, P-C ; Chen, Y-J</creatorcontrib><description>Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 ( P =0.017). The final mean central retinal thickness was 214.1±36.3  μ m, with a mean decrease of 59.8  μ m from the pre-treatment value ( P =0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</description><identifier>ISSN: 0950-222X</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/eye.2008.404</identifier><identifier>PMID: 19151652</identifier><identifier>CODEN: EYEEEC</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult ; Angiogenesis Inhibitors - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Asian Continental Ancestry Group ; Bevacizumab ; Biological and medical sciences ; China ; Choroidal Neovascularization - drug therapy ; Choroidal Neovascularization - physiopathology ; clinical-study ; Female ; Follow-Up Studies ; Fundus Oculi ; Humans ; Intravitreal Injections ; Laboratory Medicine ; Male ; Medical sciences ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Miscellaneous ; Myopia - complications ; Myopia - physiopathology ; Ophthalmology ; Pharmaceutical Sciences/Technology ; Surgery ; Surgical Oncology ; Tomography, Optical Coherence ; Vision disorders ; Visual Acuity</subject><ispartof>Eye (London), 2009-11, Vol.23 (11), p.2042-2045</ispartof><rights>Royal College of Ophthalmologists 2009</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Nov 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</citedby><cites>FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/eye.2008.404$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/eye.2008.404$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=22153366$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19151652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, P-C</creatorcontrib><creatorcontrib>Chen, Y-J</creatorcontrib><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 ( P =0.017). The final mean central retinal thickness was 214.1±36.3  μ m, with a mean decrease of 59.8  μ m from the pre-treatment value ( P =0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</description><subject>Adult</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Asian Continental Ancestry Group</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>China</subject><subject>Choroidal Neovascularization - drug therapy</subject><subject>Choroidal Neovascularization - physiopathology</subject><subject>clinical-study</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fundus Oculi</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Laboratory Medicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Miscellaneous</subject><subject>Myopia - complications</subject><subject>Myopia - physiopathology</subject><subject>Ophthalmology</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tomography, Optical Coherence</subject><subject>Vision disorders</subject><subject>Visual Acuity</subject><issn>0950-222X</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp90c1rFDEUAPAgFru23jzLIKiXzjbJ5GPGWymtLRS8WOgtvMkkmmVmsiYzK9u_vm_ZxYJIySGH_PI-CXnP6JLRqj53W7fklNZLQcUrsmBCq1IKKV6TBW0kLTnnD8fkbc4rSvFR0zfkmDVMMiX5gpjbcUqwCVNy0BdhXDk7hTgW0Ret24ANj_MAbeFjKoZtXAdb2F8xxdChHl3cQLZzDyk8wu7b14KVWwcJfd_HP-W8PiVHHvrs3h3uE3J_ffXj8qa8-_7t9vLirrSS06nkulHWa6-s7joJlINlTmrHatUJ5kTjW-ikoK2gVnsulO5aPMCqSlGtfHVCvuzjrlP8Pbs8mSFk6_oesMo5G10JVuGEBMrPL0rOeC0rxRF-_Aeu4pxG7AJNXTVCS4bobI9sijkn5806hQHS1jBqdvsxuB-z24_B7Mg_HGLO7eC6Z3xYCIJPB4CThd4nGG3Ifx3nTGLLCl25dxmfxp8uPRf338RPfjuoAQ</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Wu, P-C</creator><creator>Chen, Y-J</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7T2</scope><scope>7U2</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</title><author>Wu, P-C ; Chen, Y-J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c520t-2796cf7f6c7dd5a02ac1e57e186d41e49fbad540b40c7f2467dbdbda1336076f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adult</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Asian Continental Ancestry Group</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>China</topic><topic>Choroidal Neovascularization - drug therapy</topic><topic>Choroidal Neovascularization - physiopathology</topic><topic>clinical-study</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fundus Oculi</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Laboratory Medicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Miscellaneous</topic><topic>Myopia - complications</topic><topic>Myopia - physiopathology</topic><topic>Ophthalmology</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tomography, Optical Coherence</topic><topic>Vision disorders</topic><topic>Visual Acuity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, P-C</creatorcontrib><creatorcontrib>Chen, Y-J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health &amp; Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health &amp; Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied &amp; Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, P-C</au><au>Chen, Y-J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>23</volume><issue>11</issue><spage>2042</spage><epage>2045</epage><pages>2042-2045</pages><issn>0950-222X</issn><eissn>1476-5454</eissn><coden>EYEEEC</coden><abstract>Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 ( P =0.017). The final mean central retinal thickness was 214.1±36.3  μ m, with a mean decrease of 59.8  μ m from the pre-treatment value ( P =0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>19151652</pmid><doi>10.1038/eye.2008.404</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0950-222X
ispartof Eye (London), 2009-11, Vol.23 (11), p.2042-2045
issn 0950-222X
1476-5454
language eng
recordid cdi_proquest_miscellaneous_734134044
source MEDLINE; Springer Nature - Complete Springer Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adult
Angiogenesis Inhibitors - therapeutic use
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized
Asian Continental Ancestry Group
Bevacizumab
Biological and medical sciences
China
Choroidal Neovascularization - drug therapy
Choroidal Neovascularization - physiopathology
clinical-study
Female
Follow-Up Studies
Fundus Oculi
Humans
Intravitreal Injections
Laboratory Medicine
Male
Medical sciences
Medicine
Medicine & Public Health
Middle Aged
Miscellaneous
Myopia - complications
Myopia - physiopathology
Ophthalmology
Pharmaceutical Sciences/Technology
Surgery
Surgical Oncology
Tomography, Optical Coherence
Vision disorders
Visual Acuity
title Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T22%3A25%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intravitreal%20injection%20of%20bevacizumab%20for%20myopic%20choroidal%20neovascularization:%201-year%20follow-up&rft.jtitle=Eye%20(London)&rft.au=Wu,%20P-C&rft.date=2009-11-01&rft.volume=23&rft.issue=11&rft.spage=2042&rft.epage=2045&rft.pages=2042-2045&rft.issn=0950-222X&rft.eissn=1476-5454&rft.coden=EYEEEC&rft_id=info:doi/10.1038/eye.2008.404&rft_dat=%3Cproquest_cross%3E734134044%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=218394751&rft_id=info:pmid/19151652&rfr_iscdi=true